Verquvo 10mg (Vericiguat)

Overview

Verquvo 10mg is a prescription medication that contains Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator developed for patients with chronic heart failure (CHF), particularly those with reduced ejection fraction (HFrEF). It’s intended to lower the possibility of dying from heart disease as well as heart failure hospitalizations when patients have been stabilized following the decompensation of a recent event that required the administration of intravenous diuretics, hospitalization, or urgent intervention.

Vericiguat helps by increasing the Nitric oxide (NO)-sGC-cyclic Guanosine Monophosphate (cGMP) pathway to improve the function of the heart and blood vessels. It results in vasodilation: decreased cardiac remodeling and enhanced myocardial function.

Composition

• Active Ingredient: Vericiguat 10mg
• Dosage Form: Oral Tablet
• Packaging: Blister packs or Strip containing 14 tablets

Therapeutic Class

• Soluble Guanylate Cyclase (sGC) Stimulator
• Cardiovascular Agent
• Heart Failure Treatment

Indications

Verquvo 10mg is prescribed for:

• Treatment of chronic heart failure (NYHA Class II-IV) with reduced ejection fraction (HFrEF).
• To decrease the risk of hospitalization for heart failure in patients who have stabilized following more severe heart failure.

Mechanism of Action

Vericiguat functions through activating the soluble guanylate cyclase (sGC), an enzyme that plays a crucial part within the NO signaling pathway. When a heart fails, it is known that oxidative stress can reduce NO levels and the function of sGC, resulting in lower cGMP levels.

Directly stimulating sGC independently of NO, and sensitizing it to NO, Vericiguat boosts the levels of cGMP in cells, which can lead to:

• Vasodilation of blood vessels
• Reduction in cardiac and vascular fibrosis
• Improved myocardial relaxation and function
• Enhanced natriuresis and diuresis

This leads to an increase in cardiac output, a reduction of preload and postload, as well as overall better management of heart failure.

Dosage and Administration

• Starting Dose: 2.5 mg a day orally.
• Titration: Dose is to be increased every 2 weeks until it is tolerated, gradually increasing to 5 mg, and finally up to the dose that is targeted at 10 mg twice daily.
• Maintenance Dose: 10 mg, once a day to be taken orally along with food.
• Duration: Treatment for long-term conditions as recommended by a cardiac surgeon.

Administration Guidelines

• Take tablets whole, but don’t crush or chew.
• The medication should be taken regularly and at meals for maximum absorption.
• Avoid skipping doses. Do not miss doses as quickly as possible, even if you are close to your next dose.

Clinical Benefits

• Significantly decreases the risk of cardiovascular deaths as well as the need for hospitalization due to heart disease.
• Enhances the functional capacity and improves the quality of life for patients suffering from HFrEF.
• Works in conjunction with other guideline-directed therapies (GDMT), including ACE inhibitors, beta-blockers, and antagonists of the mineralocorticoid receptor.
• It slows the process of remodeling in the heart and reduces the risk of heart failure.

Side Effects

Common Side Effects

• Hypotension (low blood pressure)
• Dizziness
• Fatigue
• Nausea
• Anemia

Less Common/Serious Side Effects

• Syncope (fainting)
• Bradycardia (slow heart rate)
• Allergic reactions (rash, itching)
• Worsening heart failure symptoms (rare)

Contraindications

• There is a known hypersensitivity reaction to Vericiguat or any other component of the formula.
• Utilizing other nitric oxide donors or inhibitors of phosphodiesterase can lead to the possibility of severe hypotension.
• Severe hepatic impairment.
• Pregnancy and lactation (use only if benefits outweigh risks).

Precautions

• Check blood pressure frequently and especially when dose titration is being performed.
• Be cautious in patients suffering from low blood pressure or a depletion of volume.
• Renal impairment: Do not require dose adjustments; check the renal function.
• The use of antihypertensive medication in conjunction with it is a requirement for monitoring hypotension.
• Tell your doctor about the medications that you are taking to ensure there is no interaction.

Drug Interactions

• Beware of concurrent use of the nitrates or inhibitors of phosphodiesterase (e.g., sildenafil) that can cause extreme hypotension.
• Could be a risk to other drugs to reduce blood pressure, which may require dosage adjustment.
• Not a significant interaction with commonly used heart failure medications, but you should be sure to inform your physician.

Monitoring

• Heart rate and blood pressure monitoring throughout treatment and adjustment.
• Regularly assess the liver and kidney performance.
• Check for signs of heart failure progression.
• The complete Blood count (CBC) to test for anemia.

Storage

• Maintain at room temperature between 20°C and 25°C.
• Beware of extreme heat, humidity, or the direct light of the sun.
• Make sure that the area is safe for young children.
• Do not use beyond expiry date.

Patient Counseling

• Follow the doses as prescribed and do not attempt to self-adjust.
• Report dizziness, fainting, or excessive fatigue immediately.
• Avoid driving or operating heavy machinery if dizziness occurs.
• Keep regular visits to follow up with your doctor.
• Be sure to maintain a healthy lifestyle, which includes exercising and eating right.
• Discuss with your physician any other supplements or medications.

Clinical Evidence

Verquivo’s safety and efficacy were demonstrated during the VICTORIA clinical trial, comprising patients suffering from symptomatic HFrEF with a recent hospitalization for heart failure or who required diuretics intravenously. The results showed a significant decrease in the number of deaths due to cardiovascular disease or heart failure hospitalizations in comparison to the placebo.

Why Choose Verquvo?

• A novel approach that addresses a need that is not being met for the management of heart failure.
• Dosing once a day for ease and adhesion.
• It is a complement to other heart failure treatments.
• Supported by solid evidence from clinical trials.
• Increases outcomes for patients and the overall quality of life.

Summary

Verquvo 10mg (Vericiguat) is an innovative treatment for the treatment of chronic heart failure that is chronic and has decreased Ejection Fraction. Through the nitric oxide signaling pathway, Vericiguat is a revolutionary way to improve heart function. It can decrease hospitalizations and even provide lifesaving benefits. With surveillance by a physician, Verquvo offers patients a viable alternative to the treatment of heart failure.